NEW YORK, Dec 15 - GPC Biotech of Munich and Aventis announced a proteomics
collaboration Friday, in which GPC will use its Pathcode protein interaction
mapping technology to find and validate compounds that interact with a drug
target Aventis has previously identified.
The parties did not disclose the financial terms of the agreement.
This collaboration follows two other joint projects between GPC and Aventis,
one in which GPC used Pathcode to discover new antifungal targets and
another three-year project in which the companies are using genomics and
proteomics technology to identify and validate osteoarthritis drug targets.
Pathcode detects protein-protein interactions using yeast hybrid cells and
is designed to run in a high-throughput manner. GPC Biotech also offers
other proteomic and genomic technologies, such as its Reverse Genomics
cell-based screens of drug targets, to pharma and biotech companies.
In addition to Aventis, GPC also has deals with Bayer, Dupont, Boehringer
Ingelheim, Altana, Cell Genesys, Maxim Pharmaceuticals, Evotec Biosystems,
Morphosys and Karo Bio USA.